^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Anruixi (zuberitamab)

    i
    Other names: HS006, HS 006, RHCACD20MA, HS-006, RHCACD 20MA, RHCAD-20-MA
    Associations

    News

    Trials
    Company:
    Zhejiang Hisun
    Drug class:
    CD20 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1d
    Zuberitamab for EBV Infection Post-Allo-HSCT (clinicaltrials.gov)
    P2, N=20, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    |
    Anruixi (zuberitamab)
    2d
    Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
    P=N/A, N=34, Recruiting, Peking University Third Hospital
    New trial
    |
    Inokai (orelabrutinib) • pomalidomide • Anruixi (zuberitamab)
    14d
    A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy (clinicaltrials.gov)
    P2, N=135, Active, not recruiting, BioRay Pharmaceutical Co., Ltd. | Not yet recruiting --> Active, not recruiting | Trial completion date: Dec 2027 --> May 2027 | Trial primary completion date: Dec 2027 --> Mar 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Anruixi (zuberitamab)
    15d
    Cost-Effectiveness of First-Line Zuberitamab-CHOP versus Rituximab-CHOP Regimens in Untreated CD20+ Diffuse Large B-Cell Lymphoma in China. (PubMed, Risk Manag Healthc Policy)
    To conduct a cost-effectiveness analysis comparing zuberitamab combined with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone; Hi-CHOP) versus rituximab combined with CHOP (R-CHOP) as first-line therapy for previously untreated CD20-positive diffuse large B-cell lymphoma (DLBCL) patients in China. The cost-effectiveness acceptability curve (CEAC) demonstrated R-CHOP's superior cost-effectiveness probability relative to Hi-CHOP across a WTP range from $0 to $150,000. Given that Hi-CHOP is not cost-effective at conventional WTP thresholds, a substantial price reduction or unnecessary procedures, and optimizing clinical workflows for Hi-CHOP would be necessary to make it an economically viable first-line option for DLBCL compared to R-CHOP.
    Journal • HEOR • Cost-effectiveness
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Anruixi (zuberitamab)
    4ms
    ZSDT for the treatment of recurrent refractory mantle cell lymphoma after BTK inhibitor failure: a multi-center prospective clinical trial (ChiCTR2500106604)
    P4, N=30, Not yet recruiting, The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University
    New P4 trial
    |
    Xpovio (selinexor) • thalidomide • Anruixi (zuberitamab)
    4ms
    A prospective, single-arm, phase II clinical study of RCHOP (zuberitamab, cyclophosphamide, vincristine, doxorubicin, prednisone) combined with chidamide in the treatment of newly diagnosed angioimmunoblastic T-cell lymphoma with positive Ig rearrangement (ChiCTR2500106322)
    P2, N=46, Not yet recruiting, Zhejiang Cancer Hospital; Zhejiang Cancer Hospital
    New P2 trial
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Epidaza (chidamide) • Anruixi (zuberitamab)
    6ms
    BR Combined With OR in Treatment-naïve Marginal Zone Lymphoma (clinicaltrials.gov)
    P2, N=37, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    Inokai (orelabrutinib) • bendamustine • Anruixi (zuberitamab)
    8ms
    Clinical Study on Zuberitamab for treating lupus nephritis (ChiCTR2500098368)
    P4, N=60, Not yet recruiting, The First Affiliated Hospital of Wenzhou Medical University; The First Affiliated Hospital of Wenzhou Medical University
    New P4 trial
    |
    Anruixi (zuberitamab)
    8ms
    A prospective, multicenter, single-arm study of the OZB regimen (Orelabrutinib combined with zuberitamab and Bendamustine) in patients with indolent lymphoma (ChiCTR2500097927)
    P=N/A, N=48, Not yet recruiting, Taizhou Central Hospital (Affiliated Hospital of Taizhou University); Taizhou Central Hospital (Affiliated Hospital of Taizhou University)
    New trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • CCND1 (Cyclin D1)
    |
    CD20 positive • Chr t(11;14)
    |
    Inokai (orelabrutinib) • bendamustine • Anruixi (zuberitamab)
    8ms
    Efficacy and safety of Zuberitamb combined with bendamustine alternating Zuberitamab combined with high-dose cytarabine first-line induction therapy for mantle cell lymphoma: a prospective, multicenter, single-arm clinical study (ChiCTR2500096149)
    P=N/A, N=50, Not yet recruiting, Second Affliated Hospital of Army Medical University, PLA; Second Affliated Hospital of Army Medical University, PLA
    New trial
    |
    cytarabine • bendamustine • Anruixi (zuberitamab)
    11ms
    A multicenter, randomized, open label, cyclosporine controlled phase II clinical study evaluating the efficacy and safety of Zuberitamab Injection (HS006) in patients with primary membranous nephropathy (ChiCTR2400091563)
    P2, N=135, Zhongshan Hospital, Fudan University; BioRay Pharmaceutical Co.,Ltd.
    New P2 trial
    |
    Anruixi (zuberitamab)
    11ms
    Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    bendamustine • Anruixi (zuberitamab)